record_id,year,drug,indication,therapeutic_area,trial_name,trial_design,endpoint,treatment_n,control_n,treatment_response_count,control_response_count,response_rate_treatment,response_rate_control,response_rate_metric,source_url,source_section,notes,data_quality_score,response_rate_diff,nnt_type,nnt,total_n
FDAE2-1998-01,1998,Trastuzumab (Herceptin),HER2+ metastatic breast cancer (first-line),oncology,H0648g,Randomized controlled (chemo +/- trastuzumab),Overall response rate,235,234.0,45.0,29.0,0.19148936170212766,0.12393162393162394,ORR,https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/492dbdb2-077e-4064-bff3-372d6af0a7a2.xml,Table 11 (H0648g efficacy results),Combined results column: Herceptin + all chemotherapy vs all chemotherapy,4,0.06755773777050372,difference-based,14.802153432032302,469.0
FDAE2-2001-01,2001,Imatinib (Gleevec),Newly diagnosed Ph+ CML-CP,oncology,IRIS (newly diagnosed CML study),Randomized controlled (imatinib vs IFN+Ara-C),Complete hematologic response (CHR) rate,553,553.0,534.0,313.0,0.9656419529837251,0.566003616636528,CHR,https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/211ef2da-2868-4a77-8055-1cb2cd78e24b.xml,Table 18 (Response in newly diagnosed CML study),CHR rate reported as n (%) in Table 18,4,0.39963833634719714,difference-based,2.502262443438914,1106.0
FDAE2-2013-01,2013,Sofosbuvir (Sovaldi),Chronic HCV genotype 2 (interferon intolerant/ineligible),infectious disease,POSITRON,Randomized controlled (sofosbuvir+RBV vs placebo),SVR12,109,34.0,101.0,0.0,0.926605504587156,0.0,SVR12,https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/80beab2c-396e-4a37-a4dc-40fdb62859cf.xml,Table 16 (Study POSITRON: SVR12),Placebo arm reported as 0/34,4,0.926605504587156,difference-based,1.0792079207920793,143.0
FDAE2-2017-01,2017,Tisagenlecleucel (Kymriah),r/r B-cell ALL (pediatric/young adult),oncology,CCTL019B2202,Single-arm,CR/CRi,63,,52.0,,0.8253968253968254,,CR/CRi,https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/aad3ba54-dfd3-4cb3-9e2b-c5ef89559189.xml,Table 11 (Efficacy results in r/r B-cell ALL),CR/CRi rate in evaluable patients (N=63),4,,single-arm (assumes 0 baseline),1.2115384615384617,63.0
FDAE2-2017-02,2017,Axicabtagene ciloleucel (Yescarta),r/r LBCL,oncology,ZUMA-1,Single-arm,Objective response rate,101,,73.0,,0.7227722772277227,,ORR,https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/9b70606e-b99c-4272-a0f1-b5523cce0c59.xml,Table 10 (Response rate in ZUMA-1),ORR reported as 73 (72%) with N=101,4,,single-arm (assumes 0 baseline),1.3835616438356164,101.0
FDAE2-2018-01,2018,Larotrectinib (Vitrakvi),Solid tumors with NTRK gene fusions,oncology,Pooled clinical dataset,Single-arm,Overall response rate,204,,,,0.6,,ORR,https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/0c8ca614-58b2-4aa4-83d3-0387a8f782fd.xml,"Table 5 (Efficacy results, NTRK fusion tumors)",ORR reported as 60% (95% CI 55-65); count not provided,3,,single-arm (assumes 0 baseline),1.6666666666666667,204.0
